Literature DB >> 6086881

Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro.

E Richelson, A Nelson.   

Abstract

Using radioligand binding techniques, we determined the equilibrium dissociation constants (KDS) for a series of antidepressants at the histamine H1, muscarinic acetylcholine, alpha-1 and alpha-2 adrenergic and dopamine (D-2) receptors of normal human brain tissue obtained at autopsy. Twenty-five different antidepressants were studied at all but the D-2 receptor at which the number was 13 (including a metabolite of an antidepressant). Of all the receptor interactions studied, that at the histamine H1 receptor was in general the most potent interaction of this class of compounds, corresponding to results from studies using animal tissue as the source of receptors. At the human brain histamine H1 receptor, antidepressants remained among the most potent histamine H1 antagonists known, although their affinities for human receptors were lower than those for animal receptors. The most potent and the least potent compounds at the receptors were doxepin (KD = 0.24 nM) and fluvoxamine (KD = 109 microM) at the histamine H1 receptor, amitriptyline (KD = 18 nM) and trazodone (KD = 324 microM) at the muscarinic receptor, doxepin (KD = 24 nM) and viloxazine (KD = 14 microM) at the alpha-1 receptor, mianserin (KD = 73 nM) and bupropion (KD = 81 microM) at the alpha-2 receptor and amoxapine (KD = 160 nM) and trazodone (KD = 3800 nM) at the D-2 receptor, respectively. In general, compared to older drugs, the newer compounds tended to have lower affinities for these receptors.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6086881

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  65 in total

1.  Clomipramine induced neuroleptic malignant syndrome and pyrexia of unknown origin.

Authors:  Alison M Haddow; Dawn Harris; Martin Wilson; Hannah Logie
Journal:  BMJ       Date:  2004-12-04

2.  Antidepressant and Antipsychotic Drugs.

Authors:  Andrew D Krystal
Journal:  Sleep Med Clin       Date:  2010-12-01

Review 3.  Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.

Authors:  P Benfield; A Ward
Journal:  Drugs       Date:  1986-10       Impact factor: 9.546

Review 4.  Tricyclic antidepressant pharmacology and therapeutic drug interactions updated.

Authors:  P K Gillman
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

Review 5.  Pharmacology of serotonin uptake inhibitors: focus on fluvoxamine.

Authors:  P D Hrdina
Journal:  J Psychiatry Neurosci       Date:  1991-07       Impact factor: 6.186

6.  Optimizing the Pharmacologic Treatment of Insomnia: Current Status and Future Horizons.

Authors:  Jared Minkel; Andrew D Krystal
Journal:  Sleep Med Clin       Date:  2013-09-01

Review 7.  The Role of Metabolites of Antidepressants in the Treatment of Depression.

Authors:  M V Rudorfer; W Z Potter
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

Review 8.  Antidepressants. A comparative review of the clinical pharmacology and therapeutic use of the 'newer' versus the 'older' drugs.

Authors:  M V Rudorfer; W Z Potter
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

Review 9.  Drug therapy for geriatric depression.

Authors:  R Bressler; M D Katz
Journal:  Drugs Aging       Date:  1993 May-Jun       Impact factor: 3.923

10.  Pharmacological characterization of muscarine receptors of PC12 (rat phaeochromocytoma) cells.

Authors:  H Bönisch; R Boer; M Dobler; C Schudt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-03       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.